Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Svb Leerink cut their FY2019 earnings estimates for Ultragenyx Pharmaceutical in a research report issued on Tuesday, November 5th. Svb Leerink analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($7.63) per share for the year, down from their prior forecast of ($7.59). Svb Leerink also issued estimates for Ultragenyx Pharmaceutical’s Q4 2019 earnings at ($1.96) EPS, Q1 2020 earnings at ($1.92) EPS, Q2 2020 earnings at ($1.90) EPS, Q3 2020 earnings at ($1.88) EPS, Q4 2020 earnings at ($1.61) EPS, FY2020 earnings at ($7.30) EPS and FY2021 earnings at ($6.72) EPS.
Several other analysts have also recently commented on RARE. Leerink Swann reiterated a “positive” rating and issued a $85.00 target price (up from $80.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, September 4th. ValuEngine cut Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. Cowen reiterated a “buy” rating and issued a $62.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 5th. Wedbush reiterated a “buy” rating and issued a $75.00 target price on shares of Ultragenyx Pharmaceutical in a report on Thursday, August 15th. Finally, Piper Jaffray Companies set a $75.00 price target on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. Ultragenyx Pharmaceutical currently has an average rating of “Buy” and a consensus price target of $71.92.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.71) by ($0.25). The company had revenue of $25.80 million during the quarter, compared to analyst estimates of $28.88 million. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 51.40%. The firm’s revenue for the quarter was up 119.4% compared to the same quarter last year. During the same period last year, the firm earned ($1.74) EPS.
Several large investors have recently modified their holdings of RARE. Price T Rowe Associates Inc. MD raised its position in shares of Ultragenyx Pharmaceutical by 31.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock worth $292,858,000 after purchasing an additional 1,110,316 shares during the period. Nuveen Asset Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 6,239.7% during the second quarter. Nuveen Asset Management LLC now owns 275,081 shares of the biopharmaceutical company’s stock worth $17,467,000 after purchasing an additional 270,742 shares during the period. First Light Asset Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $11,431,000. Macquarie Group Ltd. raised its position in shares of Ultragenyx Pharmaceutical by 19.6% during the second quarter. Macquarie Group Ltd. now owns 797,293 shares of the biopharmaceutical company’s stock worth $50,628,000 after purchasing an additional 130,561 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Ultragenyx Pharmaceutical by 2.3% during the second quarter. Vanguard Group Inc. now owns 5,005,872 shares of the biopharmaceutical company’s stock worth $317,874,000 after purchasing an additional 112,101 shares during the period.
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis purchased 5,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were purchased at an average cost of $43.63 per share, with a total value of $218,150.00. Following the completion of the purchase, the chief executive officer now owns 472,479 shares in the company, valued at $20,614,258.77. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.80% of the stock is currently owned by insiders.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Story: Asset Allocation and Your Retirement
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.